Hoechst AG was a German chemical and pharmaceutical company founded in 1863, which grew into a global industry leader before merging with Rhône-Poulenc to form Aventis in 1999 and later being acquired by Sanofi. The timeline covers its founding, key product breakthroughs, executive leadership, wartime involvement, post-war recovery, international expansion, and eventual dissolution.
Chemists Eugen Lucius, Wilhelm Meister, and Ludwig August Müller found a dye works in Höchst am Main, Germany, initially called Teerfarbenfabrik Meister, Lucius & Co. #chemical #history
The company begins producing fuchsine, a magenta dye, marking its entry into the synthetic dye market. #chemical #dye
The firm is reorganized as a joint-stock company (Aktiengesellschaft) named Farbwerke vorm. Meister Lucius & Brüning, expanding capital for growth. #business #history
Hoechst begins producing pharmaceuticals, starting with antipyrine, a pain reliever, expanding beyond dyes. #pharma #chemical
Chemist Alfred Einhorn synthesizes procaine, marketed as Novocaine, a major breakthrough in local anesthesia. #pharma #innovation
Paul Ehrlich, working with Hoechst, develops Salvarsan, the first effective treatment for syphilis, revolutionizing medicine. #pharma #history
Hoechst markets Salvarsan commercially, becoming a leader in chemotherapy. #pharma #innovation
Hoechst merges with BASF, Bayer, and other companies to form IG Farben, a massive chemical conglomerate. #chemical #merger
Hoechst scientists develop a process for synthetic insulin production, improving diabetes treatment. #pharma #biotech
Hoechst launches Prontosil, the first sulfonamide antibiotic, discovered by Gerhard Domagk, saving countless lives. #pharma #antibiotic
After WWII, the IG Farben plants, including Hoechst, are dismantled or seized; Hoechst's headquarters in Frankfurt is rebuilt. #history #chemical
IG Farben is liquidated; Hoechst AG is re-established as an independent company, inheriting dye and pharmaceutical assets. #merger #history
Carl Wurster takes leadership, overseeing Hoechst's rapid expansion and diversification into plastics and fibers. #leadership #chemical
Hoechst introduces Hostacyclin (tetracycline), a broad-spectrum antibiotic, boosting pharmaceutical sales. #pharma #antibiotic
Hoechst develops Hostalen (high-density polyethylene), entering the plastics market. #chemical #plastics
Hoechst establishes American Hoechst Corporation in the United States, marking international expansion. #business #global
Hoechst shares are listed on the Frankfurt Stock Exchange, increasing capital for growth. #finance #stock
Hoechst invests in wastewater treatment plants and environmental technology, responding to growing ecological concerns. #environment #chemical
The 1973 oil crisis raises raw material costs, prompting Hoechst to restructure and focus on high-value pharmaceuticals. #business #crisis
Hoechst introduces the antibiotic Claforan, a third-generation cephalosporin, generating significant revenue. #pharma #antibiotic
Hoechst acquires a controlling stake in French pharmaceutical company Roussel Uclaf, expanding in Europe. #merger #pharma
Hoechst buys Celanese, a U.S. chemical and fibers company, for $2.8 billion, becoming a major player in specialty chemicals. #merger #chemical
Hoechst merges its chemical operations with Celanese to form Hoechst Celanese Corporation, a leading chemical producer. #merger #chemical
Hoechst strengthens its agrochemical division through acquisitions and research, focusing on crop protection. #agrochemical #business
Jürgen Dormann takes over as CEO, emphasizing pharmaceutical and life sciences as core businesses. #leadership #pharma
Hoechst researchers contribute to early stem cell technology, though controversial. #biotech #research
Hoechst spins off Hoechst Celanese as an independent company to focus on pharmaceuticals and life sciences. #divestiture #chemical
Hoechst acquires Marion Merrell Dow, a U.S. pharmaceutical company, strengthening its drug portfolio. #merger #pharma
Hoechst merges with French company Rhône-Poulenc to create Aventis, a global life sciences leader. #merger #pharma
Aventis SA is formally established, combining Hoechst and Rhône-Poulenc's pharmaceutical and agricultural divisions. #business #pharma
Aventis spins off its crop science division as Aventis CropScience, later sold to Bayer. #divestiture #agrochemical
Aventis reports declining profits due to generic competition and patent expirations, leading to cost-cutting measures. #finance #pharma
French pharmaceutical Sanofi-Synthélabo launches a hostile takeover bid for Aventis, sparking a battle. #merger #hostile
Sanofi successfully acquires Aventis for €55 billion, creating Sanofi-Aventis, now Sanofi. Hoechst AG ceases to exist. #merger #pharma
The Hoechst brand is gradually phased out, with operations fully integrated into Sanofi-Aventis. #business #history
Sanofi-Aventis drops 'Aventis' from its name, becoming simply Sanofi, erasing the Hoechst name from the corporate identity. #corporate #history